Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: Progress to date

Pediatric Drugs

Volumn 9, Issue 6, 2007, Pages 371-378

  Marks, Stephen D ^a,b,c   Tullus, Kjell ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

B cell inhibitors, therapeutic use; Children; Epratuzumab, therapeutic use; Ocrelizumab, therapeutic use; Research and development; Rituximab, therapeutic use; Systemic lupus erythematosus, treatment

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB;

APOPTOSIS; B LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DECUBITUS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; HERPES; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPETIGO; IN VITRO STUDY; INFECTION; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MENINGITIS; NEUTROPENIA; PANCYTOPENIA; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEPTICEMIA; SERUM SICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHILD; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION;

EID: 36749053444     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709060-00004     Document Type: Review

References (54)

1. Baqi N, Moazami S, Singh A, et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996; 7 (6): 924-9
2. Bogdanovic R, Nikolic V, Pasic S, et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 2004; 19 (1): 36-44
3. Font J, Cervera R, Espinosa G, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998; 57 (8): 456-9
4. Glidden RS, Mantzouranis EC, Borel Y. Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983; 29 (2): 196-210
5. Marini R, Costallat LT. Young age at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus. Rev Rhum Engl Ed 1999; 66 (6): 303-9
6. Walravens PA, Chase HP. The prognosis of childhood systemic lupus erythematosus. Am J Dis Child 1976; 130 (9): 929-33
7. Wang LC, Yang YH, Lu MY, et al. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect 2003; 36 (3): 203-8
8. Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998; 160 (1): 51-9
9. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 107-21
10. Reininger L, Winkler TH, Kalberer CP, et al. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB x NZW)F1 mice. J Exp Med 1996; 184 (3): 853-61
11. Dar O, Salaman MR, Seifert MH, et al. B lymphocyte activation in systemic lupus erythematosus: spontaneous production of IgG antibodies to DNA and environmental antigens in cultures of blood mononuclear cells. Clin Exp Immunol 1988; 73 (3): 430-5
12. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165 (10): 5970-9
13. Odendahl M, Keitzer R, Wahn U, et al. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 2003; 62 (9): 851-8
14. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66: 1933-48
15. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40 (2): 205-11
16. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003; 17 (5): 417-22
17. Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease. Arthritis Res Ther 2003; 5 Suppl. 4: S17-21
18. Hainsworth JD, Burris III HA, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95 (10): 3052-6
19. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004; 4 (4): 398-402
20. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50 (8): 2580-9
21. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48 (2): 455-9
22. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50 (11): 3580-90
23. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46 (10): 2673-7
24. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44 (12): 1542-5
25. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54 (11): 3612-22
26. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8 (3): R83
27. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54 (9): 2970-82
28. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8 (6): R167
29. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-5
30. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52 (2): 501-13
31. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64 (6): 913-20
32. Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2006; 24 (1): 65-9
33. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52 (10): 3168-74
34. Marks SD, Tullus K. Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol 2006; 21 (4): 598-9
35. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148 (5): 623-7
36. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8 (3): R74
37. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus. 2006; 66 (15): 1933-48
38. Saito B, Nakamaki T, Adachi D, et al. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004; 80 (2): 164-7
39. Cheson BD. Rituximab: clinical development and future directions. Expert Opin Biol Ther 2002; 2 (1): 97-110
40. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999; 17 (6): 1962-3
41. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94 (7): 2217-24
42. US Food and Drug Administration. Rituximab (marketed as Rituxan). Information for healthcare professionals [online]. Available from URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/rituximab.pdf [Accessed 2007 Nov 1]
43. US Food and Drug Administration. Rituxan warning. FDA Consum 2007 Mar-Apr; 41 (2): 3
44. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99 (4): 1486-8
45. Steurer M, Clausen J, Gotwald T, et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation 2003; 76 (2): 435-6
46. Freim Wahl SG, Folvik MR, Torp SH. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 2007; 26 (2): 68-73
47. Matteucci P, Magni M, Di NM, et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002; 100 (3): 1104-5
48. Garcia-Suarez J, de MD, Krsnik I, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80 (4): 271-81
49. Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol 1994; 8 (2): 230-49
50. Emre S, Bilge I, Sirin A, et al. Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 2001; 87 (2): 118-26
51. Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002; 29 (12): 2635-42
52. Khoo J, Pee S, Thevarajah B, et al. Lupus nephritis in children in Malaysia. J Paediatr Child Health 2005; 41 (1-2): 31-5
53. Yang LY, Chen WP, Lin CY. Lupus nephritis in children: a review of 167 patients. Pediatrics 1994; 94 (3): 335-40
54. Zappitelli M, Duffy C, Bernard C, et al. Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr Nephrol 2004; 19 (5): 503-10